Southeast Georgia Health System was recently selected as a research site
to participate in Agendia’s Neoadjuvant Breast Registry-Symphony
The purpose of the study is to assess information obtained from the Agendia
Breast Cancer Suite of diagnostic tests and other clinical information
to study ways to assist in breast cancer diagnosis and treatment decisions.
These tests may allow physicians to more accurately tailor therapy for
each breast cancer patient by working with the patient’s specific
clinical pathology to personalize his or her treatment plan.
Principal investigator Antonio Moran Jr., M.D., FACP,medical oncologist,Southeast
Georgia Physician Associates-Hematology & Oncology, will work with
co-investigators Vincent K. Arlauskas, M.D., general surgeon, Southeast
Georgia Physician Associates-Glynn General & Vascular Surgery, Bruce
Tripp, M.D., radiation oncologist,Southeast Georgia Physician Associates-Radiation
Oncology, and T. Wayne Rentz Jr., M.D., general surgeon,Southeast Georgia
Physician Associates-Brunswick General Surgery, in addition to multiple
Health System team members, to contribute clinical information for this
Research from a large body of studies suggests that patients with breast
cancer have different risks for their tumors spreading and may respond
better to specific therapies. Although definitive studies to determine
which therapies are best are not yet available today, the test is--in
effect--documenting the unique "fingerprint" of a woman’s
tumor and may hold the key to a greater level of personalized treatment
for her and for other women in the future.
"This is a very important study and we are very fortunate to be involved
in this trial," says Dr. Moran. "Genomic technology is the future
of oncology. Using molecular biologic information, we can be more specific
about who will not likely relapse without any intervention, who will need
aggressive therapy, and who will need hormonal therapy. This cutting edge
technology is evolving rapidly, and we are proud to be involved."
For additional information, please visit
www.clinicaltrials.gov and search NBRST.